EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases?

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.4K citations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Andrew Weickhardt, Benjamin Scheier, Joseph Burke et al. · Journal of Thoracic Oncology · 2012 · 663 citations · Full text

Local Ablative Therapy, Oncology, Novel Therapy +8

Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer

James W. Welsh, Ritsuko Komaki, Arya Amini et al. · Journal of Clinical Oncology · 2013 · 392 citations · Full text

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Timothy A. Yap, Laura Vidal, Jan Adam et al. · Journal of Clinical Oncology · 2010 · 342 citations · Full text